Is your mAb optimized for
SubQ yet?
Cutting edge, viscosity-reduction technology for
monoclonal antibodies
This patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.
HILOPRO Technology
®
Upgrade your mAb from IV to SubQ.
Re-imagine your biologic API delivered subcutaneously in a single dose up to 375mg in a 1.5mL syringe.
Proof of concept for your mAb in
8 Weeks !
